A Phase 2 Multi-center, Randomized, Double-blind, Comparator-Controlled Dose Finding Study to Evaluate MP4CO for the Acute Treatment of Vaso-occlusive Crises in Subjects With Sickle Cell Disease
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 03 Aug 2017
Price : $35 *
At a glance
- Drugs MP4CO (Primary) ; Sodium chloride
- Indications Sickle cell anaemia; Veno-occlusive disorders
- Focus Therapeutic Use
- Sponsors Sangart
- 03 Aug 2017 This trial has been discontinued in Belgium.
- 24 Sep 2014 New source identified and integrated (European Clinical Trials Database - EudraCT2013-001600-11).
- 04 Nov 2013 New trial record